Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.

@article{Sieniawski2010EvaluationOE,
  title={Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.},
  author={Michal Sieniawski and Nithia Angamuthu and Karen Boyd and Richard Chasty and John Davies and Peter Forsyth and Fergus Jack and Simon Lyons and Philip J Mounter and Paula A. Revell and Stephen J. Proctor and Anne L. Lennard},
  journal={Blood},
  year={2010},
  volume={115 18},
  pages={
          3664-70
        }
}
Enteropathy associated T-cell lymphoma (EATL) is a rare type of peripheral T-cell lymphoma. At present, there are no standardized diagnostic or treatment protocols for EATL. We describe EATL in a population-based setting and evaluate a new treatment with aggressive chemotherapy and autologous stem cell transplantation (ASCT). From 1979 onward the Scotland and Newcastle Lymphoma Group prospectively collected data on all patients newly diagnosed with lymphoma in the Northern Region of England and… 

Figures and Tables from this paper

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

A review of recently published data on epidemiology and clinical features, as well as standard and novel treatments including high-dose chemotherapy with ASCT and their outcome inEnteropathy-associated T-cell lymphoma.

Treatment response in enteropathy associated T‐cell lymphoma; survival in a large multicenter cohort

It is indicated that combination treatment is superior compared to monotherapy and whether or not consolidation therapy with autologous SCT may improve survival needs to be substantiated in a larger randomized international trial.

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.

Autologous stem cell transplantation was retrospectively evaluated as a consolidation or salvage strategy forEnteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of the patients.

Enteropathy-Associated T-Cell Lymphoma: Improving Treatment Strategies

Intensification of therapy using high-dose chemotherapy followed by consolidation with BEAM and autologous stem cell transplantation is associated with better outcome and Brentuximab vedotin (anti-CD30) might be promising when added to conventional chemotherapy and is suggested as upfront treatment in EATL.

Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project.

The study confirms the poor prognosis of patients with EATL and the need for improved treatment options and the International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostics Index for Peripheral T-Cell Lymphoma (PIT).

Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis

A retrospective analysis of 19 patients with EATL identified six patients (31%) undergoing second line chemotherapy after CHOP-like regimens, and data again confirm the poor prognosis of patients withEATL.

Enteropathy-Associated T cell Lymphoma

EATL is an aggressive peripheral T cell lymphoma with poor overall treatment outcome using currently available therapy options and the role of targeted and biologic therapies in newly diagnosed EATL patients along with relapsed, refractory cases is evolving and discussed in this review.

Standard of Care in T-Cell Lymphoma

This chapter reviews the current approach to peripheral T-cell lymphoma in terms of clinical evaluation, diagnosis, staging, and first-line treatment and presents possible treatment options for patients whose disease recurs after chemotherapy or appears refractory.

Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.

...

References

SHOWING 1-10 OF 40 REFERENCES

Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma.

  • A. Al-TomaW. Verbeek P. Huijgens
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2007

Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.

The prognosis for these patients with a diagnosis of enteropathy-type intestinal T-cell lymphoma treated at the Wessex Regional Medical Oncology Unit in Southampton between 1979 and 1996 is poor; it is encouraging that there are five long-term survivors.

Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.

Preliminary results showed that high-dose chemotherapy followed by ASCT seems feasible and safe and might result in long-term improvement of patients with RCD type II whose condition did not respond promptly to available drugs.

Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.

IEV is a predictable and highly effective mobilization regimen in relapsed/refractory patients with aggressive NHL or HD and indicates the efficacy of the IEV regimen in inducing a good remission rate.

Successful Treatment of Enteropathy-Associated T Cell Lymphoma with Autologous Stem Cell Transplant

A 1-year trial of a strict gluten-free diet, 6-mercaptopurine, 50 mg daily, and a rotating course of antibiotics initially improved the patient’s symptoms, but she was still admitted for pseudoobstruction.

High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.

One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i.v. daily

CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation.

Although the prognosis of ITCL has been considered to be very poor irrespective of CD56 positivity, complete remission was achieved in this case by high dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) even after relapse.

Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience

Remarkably, no patient with RCD I developed RCD II or EATL within the mean follow-up period of 5 years (range 2–15 years), and more aggressive and targeted therapies seem necessary in R CD II and EATl.

18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease.

18F-FDG PET, in addition to conventional CT, is recommended for evaluating patients with RCD and is shown to be more sensitive and specific than CT.

Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.

  • S. DaumR. Ullrich E. Riecken
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
IBCL patients at stages EI and EII respond well to chemotherapy, but the prognosis and treatment of ITCL patients is unsatisfactory, according to a prospective, nonrandomized multicenter study.